Mukesh Harisinghani, MD
Professor of Radiology, Harvard Medical School
Radiologist, Dept. of Abdominal Imaging

Phone: 617-726-8396

Design and conduct clinical trials and provide an avenue for clinical testing of novel imaging agents developed at CMIR.

Over the last several years we have conducted phase 1,2 and phase 3 clinical trials of monocrystalline iron oxides (1-2) for a number of applications. Current trials evaluate the efficacy of these agents to improve detection of subtle lymph node metastases in patients with prostate cancer (funded in part by RSNA) and renal cancer (funded in part by by SCBT).

My primary clinical interests lie in abdominal and pelvic MR imaging

Hedgire SS, Mino-Kenudson M, Elmi A, Thayer S, Fernandez-Del Castillo C, Harisinghani MG
Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation.
Int J Nanomedicine. 2014;9:1891-1896 - PMID: 24790431 - PMCID: PMC4000182
Hedgire SS, Eberhardt SC, Borczuk R, McDermott S, Harisinghani MG
Interpretation and reporting multiparametric prostate MRI: a primer for residents and novices.
Abdom Imaging. 2014;:ePub - PMID: 24566965
Harisinghani MG
The male pelvis.
Magn Reson Imaging Clin N Am. 2014;22(2):xi - PMID: 24792681
Hedgire SS, Tabatabaei S, McDermott S, Feldman A, Dahl DM, Harisinghani MG
Diversion ahead: imaging appearance of urinary diversions and reservoirs.
Clin Imaging. 2014;38(4):418-427 - PMID: 24602415
Hedgire SS, Elmi A, Kambadakone AR, Yoon S, Blake M, Harisinghani MG
MDCT imaging of Alloderm biologic mesh spacers in the abdomen and pelvis - preliminary experience.
Clin Imaging. 2014;38(3):279-82 - PMID: 24556330